DAWN vs. XNCR, MORF, PTGX, AKRO, DVAX, KNSA, RCUS, ANIP, TARO, and KURA
Should you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Xencor (XNCR), Morphic (MORF), Protagonist Therapeutics (PTGX), Akero Therapeutics (AKRO), Dynavax Technologies (DVAX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), ANI Pharmaceuticals (ANIP), Taro Pharmaceutical Industries (TARO), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical preparations" industry.
Xencor (NASDAQ:XNCR) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.
Xencor presently has a consensus price target of $36.25, suggesting a potential upside of 61.25%. Day One Biopharmaceuticals has a consensus price target of $37.67, suggesting a potential upside of 135.42%. Given Xencor's higher possible upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than Xencor.
In the previous week, Day One Biopharmaceuticals had 28 more articles in the media than Xencor. MarketBeat recorded 40 mentions for Day One Biopharmaceuticals and 12 mentions for Xencor. Xencor's average media sentiment score of 0.04 beat Day One Biopharmaceuticals' score of -0.07 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media.
Day One Biopharmaceuticals has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -82.23%. Day One Biopharmaceuticals' return on equity of -19.83% beat Xencor's return on equity.
88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 5.2% of Xencor shares are owned by company insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Xencor has higher revenue and earnings than Day One Biopharmaceuticals. Xencor is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Xencor received 460 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 72.89% of users gave Xencor an outperform vote while only 58.18% of users gave Day One Biopharmaceuticals an outperform vote.
Xencor has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.44, indicating that its stock price is 244% less volatile than the S&P 500.
Summary
Xencor beats Day One Biopharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Day One Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Day One Biopharmaceuticals Competitors List
Related Companies and Tools
